Evidence map›Paper›PMID 40768871›Full record

ArticleAddictive behaviors2025

Tobacco and cannabis use among pregnant women with prenatal opioid use.

E Melinda Mahabee-Gittens, Nicole Mack, Carla M Bann, Jamie E Newman, Junfang Zhao, Kenneth D R Setchell, Lara Stone, Namasivayam Ambalavanan, Myriam Peralta-Carcelen, Sara B DeMauro and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addictive behaviors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

E Melinda Mahabee-GittensCincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, OH 45229, USA. Electronic address: melinda.mahabee-gittens@cchmc.org.
Nicole MackAnalytics Division, RTI International, Research Triangle Park, NC 27709, USA.
Carla M BannAnalytics Division, RTI International, Research Triangle Park, NC 27709, USA.
Jamie E NewmanAnalytics Division, RTI International, Research Triangle Park, NC 27709, USA.
Junfang ZhaoDivision of Pathology & Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Kenneth D R SetchellDepartment of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, OH 45229, USA; Division of Pathology & Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Lara StoneCincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Namasivayam AmbalavananDivision of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Myriam Peralta-CarcelenDivision of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Sara B DeMauroDivision of Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Scott A LorchDivision of Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Deanne E Wilson-CostelloDivision of Neonatology, Department of Pediatrics, Case Western Reserve University, Cleveland, OH 44106, USA.
Brenda B PoindexterDivision of Neonatology, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA.
Catherine LimperopoulosDeveloping Brain Institute, Children's National Hospital, Washington, DC 20010, USA.
Jonathan M DavisDivision of Newborn Medicine, Department of Pediatrics, Tufts Medical Center, Boston, MA 02111, USA.
Stephanie L MerharDepartment of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, OH 45229, USA; Division of Neonatology, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.

Funding

Prevalence and Clinical Correlates of Thirdhand Smoke Exposure in a Pediatric Patient PopulationR01ES030743 · NIEHS · CINCINNATI CHILDRENS HOSP MED CTR · PI MAHABEE-GITTENS, E. MELINDA · 2019 to 2023
$2.9M
HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study ConsortiumUG1HD104252 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI Sara Bonamo DeMauro, Scott A Lorch · 2024 to 2026
$425k
CWRU Clinical Center - Outcomes of Babies with Opioid Exposure (OBOE) StudyUG1HD104253 · NICHD · CASE WESTERN RESERVE UNIVERSITY · PI Anna Maria Hibbs, DEANNE E WILSON-COSTELLO · 2024 to 2026
$395k
HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study ConsortiumRL1HD104252 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI DEMAURO, SARA BONAMO · 2020 to 2020
$0k
CWRU Site for HEAL: Longitudinal Initiative in Opioid Exposed NewbornsRL1HD104253 · NICHD · CASE WESTERN RESERVE UNIVERSITY · PI WILSON-COSTELLO, DEANNE E · 2020 to 2020
$0k
Cincinnati Outcomes of Babies with Opioid Exposure (OBOE)RL1HD104254 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI MERHAR, STEPHANIE L · 2020 to 2020
$0k
NICHD NIH HHS RL1 HD104252NICHD NIH HHS RL1 HD104253NICHD NIH HHS RL1 HD104254NICHD NIH HHS UG1 HD104252NICHD NIH HHS UG1 HD104253NIEHS NIH HHS R01 ES030743
6 · The paper itself

Abstract

backgroundThere is a paucity of information on tobacco and cannabis use patterns in pregnant women who use opioids. Our objective was to examine sociodemographic, tobacco, and cannabis use patterns during pregnancy among pregnant women with opioid use.

methodsWe recruited 206 pregnant women with biochemically verified opioid use during pregnancy, of whom 98 self-reported taking only medications for opioid use disorder (MOUD) and 108 reported taking other opioids during pregnancy. We examined sociodemographic characteristics and self-report of tobacco and cannabis use overall and by trimester. Chi-square and t-tests were used to assess differences between the MOUD-only vs other opioids groups. Logistic regression models were used to examine differences in factors associated with tobacco and cannabis use.

resultsMean (SD) age was 30.7 years (4.6); 81.9 % were non-Hispanic White, and 92.6 % had public insurance. Of the 91 women taking MOUD only and completing the substance use self-report, 50 (54.9 %) reported tobacco use only, 3 (3.3 %) reported cannabis use only, and 24 (26.4 %) reported both tobacco and cannabis use. Tobacco and cannabis use was similar for women taking other opioids (p = 0.98). Adjusted odds ratios indicated that there was consistent use of all tobacco products (p = 0.28) including e-cigarette products (p = 0.18) throughout all 3 trimesters of pregnancy. There was decreased use of cannabis over the course of pregnancy with 29.8 % using cannabis during the first trimester and 16.5 % during the last trimester (p = 0.0003).

conclusionsWhile we observed no differences in tobacco and cannabis use between those taking MOUD only versus other opioids, we observed high rates of tobacco and cannabis use among pregnant women with opioid use. These findings underscore the need for tobacco and cannabis use education and cessation interventions throughout pregnancy for those with OUD.

Indexed as

Marijuana UseOpioid-Related DisordersPregnancy ComplicationsTobacco UseAdultAnalgesics, OpioidFemaleHumansPregnancyPregnant PeopleSelf ReportYoung AdultAnalgesics, OpioidCannabisElectronic cigarettesOpioid use disorderPregnancySubstance use disorderTobacco

Identifiers

PMID40768871
PMCPMC13110395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.